Literature DB >> 27340936

HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Clémence Coudre1, Julien Alani1, William Ritchie2, Véronique Marsaud3, Brigitte Sola1, Julie Cahu1.   

Abstract

Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of de novo or acquired resistance. Delineating the mechanisms of MM resistance is essential for therapeutic advances. We previously showed that long-term genotoxic stress induces the establishment of a senescence-associated secretory phenotype, a pro-inflammatory response that favors the emergence of cells with cancer stem-like properties. Here, we studied the short-term response of MM cells following treatment with various DNA damaging agents such as the energetic C-ion irradiation. MM cells are highly resistant to all treatments and do not enter apoptosis after they arrest cycling at the G2 phase. Although the DNA damage response pathway was activated, DNA breaks remained chronically in damaged MM cells. We found, using a transcriptomic approach that RAD50, a major DNA repair gene was downregulated early after genotoxic stress. In two gerosuppression situations: induction of hypoxia and inhibition of the mammalian target of rapamycin (mTOR) pathway, we observed, after the treatment with a DNA damaging agent, a normalization of RAD50 expression concomitant with the absence of cell cycle arrest. We propose that combining inhibitors of mTOR with genotoxic agents could avoid MM cells to senesce and secrete pro-inflammatory factors responsible for cancer stem-like cell emergence and, in turn, relapse of MM patients.

Entities:  

Keywords:  DNA damage response; DNA repair; cancer stem-like cell; cell cycle arrest; irradiation; mTOR; senescence

Mesh:

Substances:

Year:  2016        PMID: 27340936      PMCID: PMC4993538          DOI: 10.1080/15384101.2016.1196302

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  51 in total

1.  RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase.

Authors:  S Le; J K Moore; J E Haber; C W Greider
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

2.  Relevance of cyclin D1 level in the pathogenesis of multiple myeloma.

Authors:  Brigitte Sola; Xavier Troussard
Journal:  Blood       Date:  2003-12-01       Impact factor: 22.113

Review 3.  Senescence and apoptosis: dueling or complementary cell fates?

Authors:  Bennett G Childs; Darren J Baker; James L Kirkland; Judith Campisi; Jan M van Deursen
Journal:  EMBO Rep       Date:  2014-10-13       Impact factor: 8.807

Review 4.  SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model.

Authors:  Yu Wang; Yan Liang; Paul M Vanhoutte
Journal:  FEBS Lett       Date:  2010-12-02       Impact factor: 4.124

5.  Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Authors:  Jana Jakubikova; Sophia Adamia; Maria Kost-Alimova; Steffen Klippel; David Cervi; John F Daley; Dana Cholujova; Sun-Young Kong; Merav Leiba; Simona Blotta; Melissa Ooi; Jake Delmore; Jacob Laubach; Paul G Richardson; Jan Sedlak; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2011-02-14       Impact factor: 22.113

6.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Authors:  William Matsui; Qiuju Wang; James P Barber; Sarah Brennan; B Douglas Smith; Ivan Borrello; Ian McNiece; Lan Lin; Richard F Ambinder; Craig Peacock; D Neil Watkins; Carol Ann Huff; Richard J Jones
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Authors:  Olga V Leontieva; Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2015-09-15

Review 8.  Therapeutic advancements in multiple myeloma.

Authors:  Alessandro Gozzetti; Veronica Candi; Giulia Papini; Monica Bocchia
Journal:  Front Oncol       Date:  2014-09-04       Impact factor: 6.244

9.  Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.

Authors:  H Dorota Halicka; Hong Zhao; Jiangwei Li; Yong-Syu Lee; Tze-Chen Hsieh; Joseph M Wu; Zbigniew Darzynkiewicz
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

10.  Dramatic increase in oxidative stress in carbon-irradiated normal human skin fibroblasts.

Authors:  Carine Laurent; Alexandre Leduc; Ivannah Pottier; Virginie Prévost; François Sichel; Jean-Louis Lefaix
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more
  6 in total

1.  Senescence: Adaptation to DNA repair targeting drugs?

Authors:  Olivier Coqueret
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

2.  Cyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells.

Authors:  M Caillot; J Bourgeais; H Dakik; É Costé; N M Mazure; É Lelièvre; O Coqueret; O Hérault; F Mazurier; B Sola
Journal:  Oncogenesis       Date:  2020-07-24       Impact factor: 7.485

3.  Rapamycin, proliferation and geroconversion to senescence.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2018-12-12       Impact factor: 4.534

4.  A predicted risk score based on the expression of 16 autophagy-related genes for multiple myeloma survival.

Authors:  Fang-Xiao Zhu; Xiao-Tao Wang; Hui-Qiong Zeng; Zhi-Hua Yin; Zhi-Zhong Ye
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

Review 5.  The Great Escape: The Power of Cancer Stem Cells to Evade Programmed Cell Death.

Authors:  Vanessa Castelli; Antonio Giordano; Elisabetta Benedetti; Francesco Giansanti; Massimiliano Quintiliani; Annamaria Cimini; Michele d'Angelo
Journal:  Cancers (Basel)       Date:  2021-01-17       Impact factor: 6.639

6.  Resistance to drugs and cell death in cancer stem cells (CSCs).

Authors:  Ahmad R Safa
Journal:  J Transl Sci       Date:  2019-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.